SciBX: Science-Business eXchange Contents: September 22 2011, Volume 4 / Issue 37

TABLE OF CONTENTS September 22 2011, Volume 4 / Issue 37 Analysis Cover Story Targets and Mechanisms Tools The Distillery: Therapeutics Cancer Cardiovascular disease Endocrine disease Infectious disease Neurology The Distillery: Techniques Disease models Drug platforms Markers Recommend to your library Web feed Available online only Subscribe Advertisement SciBX: Science-Business eXchange Recommend SciBX to your library today SciBx is a weekly publication that identifies and analyzes the most important translational research articles from over 40 journals. Find out which papers have real scientific and commercial potential, and why. Subscribe to SciBX and you won't miss the next big thing. For more information visit: www.nature.com/scibx.   Trade Secrets A Nature Network blog by BIOENTREPRENEUR Brought to you by Nature Biotechnology Access the insights, advice and commentary from scientists and entrepreneurs building biotech sectors around the world. Join the global dialogue on life science entrepreneurship: http://blogs.nature.com/trade_secrets   Analysis Cover Story Top Finding the repurpose Tracey Baas doi:10.1038/scibx.2011.1030 A Stanford spinout called NuMedii will use a new computational approach to look for drug repurposing opportunities. The university's team already has in vivo data to support two opportunities: the anticonvulsant topiramate for inflammatory bowel disease and the ulcer drug cimetidine to treat lung adenocarcinoma. Full Text | PDF Targets and Mechanisms Top Optimism about oxytocin Lev Osherovich doi:10.1038/scibx.2011.1031 UCLA researchers have evidence of a link between psychological disposition and a receptor for the neuroactive hormone oxytocin. A new biotech called Pastorus says the findings provide additional proof of concept for targeting the oxytocin receptor in behavioral and psychiatric indications. Full Text | PDF STK33 strikes out Lev Osherovich doi:10.1038/scibx.2011.1032 Amgen has dropped its STK33 program after company scientists were unable to reproduce academic findings that serine/threonine kinase 33 could be a target for treating tumors driven by K-Ras mutations. Full Text | PDF Tools Top Smegmatis meets tuberculosis Kai-Jye Lou doi:10.1038/scibx.2011.1033 The organization Aeras is working with Albert Einstein College of Medicine researchers to develop a tuberculosis vaccine employing a vector the medical school team has used to produce large decreases in bacterial burden in mice. The technology could be a platform for use in other vaccine settings. Full Text | PDF Distillery: Therapeutics Cancer Top Heat shock protein 90 (Hsp90); Hsp70 doi:10.1038/scibx.2011.1034 In vitro studies identified an Hsp90 inhibitor that could help treat breast cancer. Full Text | PDF Glutathione S-transferase ω1 (GSTO1) doi:10.1038/scibx.2011.1035 In vitro studies identified GSTO1 inhibitors that could help treat cancer. Full Text | PDF HER2 (EGFR2; ERBB2; neu); neuregulin 1 (NRG1) doi:10.1038/scibx.2011.1036 In vitro, mouse and patient studies suggest HER2 inhibitors could help treat EGFR inhibitor–resistant cancer. Full Text | PDF Not applicable doi:10.1038/scibx.2011.1037 In vitro and mouse studies identified illudin M–based compounds that could help treat cancer. Full Text | PDF Serine/threonine kinase 33 (STK33) doi:10.1038/scibx.2011.1038 Cell culture studies suggest inhibiting STK33 may not help treat cancer. Full Text | PDF Tissue factor doi:10.1038/scibx.2011.1039 Mouse studies suggest inhibiting the tissue factor–activated coagulation cascade could help treat cancer. Full Text | PDF Cardiovascular disease Top ATPase Ca++ transporting cardiac muscle slow twitch 2 (ATP2A2; SERCA2A); SMT3 suppressor of mif two 3 homolog 1 (SUMO1) doi:10.1038/scibx.2011.1040 Studies in mice and in patient samples suggest upregulating cardiac SUMO1 could help treat heart failure. Full Text | PDF CXC chemokine receptor 2 (CXCR2; IL8RB) doi:10.1038/scibx.2011.1041 In vitro and mouse studies suggest CXCR2 antagonists could help treat familial pulmonary arterial hypertension (PAH). Full Text | PDF Endocrine disease Top β-Site APP-cleaving enzyme 2 (BACE2); BACE1; transmembrane protein 27 (TMEM27) doi:10.1038/scibx.2011.1042 Cell culture and mouse studies suggest preventing TMEM27 cleavage by inhibiting BACE2 could help treat type 2 diabetes. Full Text | PDF p38 Mitogen-activated protein kinase (p38 MAPK; MAPK14); X-box binding protein 1 (XBP1) doi:10.1038/scibx.2011.1043 Mouse studies suggest p38 MAPK activation in the liver could help treat type 2 diabetes. Full Text | PDF Infectious disease Top Lysine-specific histone demethylase 1 (KDM1A; LSD1) doi:10.1038/scibx.2011.1044 In vitro studies suggest inhibiting LSD1 could prevent reactivation of latent HIV. Full Text | PDF ADAM10 doi:10.1038/scibx.2011.1045 Mouse studies suggest inhibiting the α-hemolysin receptor ADAM10 could help treat staphylococcal pneumonia. Full Text | PDF DNA-damage-inducible transcript 4 (DDIT4; RTP801; REDD1) doi:10.1038/scibx.2011.1046 In vitro and cell culture studies suggest inducing REDD1 expression could help treat viral infection. Full Text | PDF Neurology Top Protein kinase Cε (PKCE) doi:10.1038/scibx.2011.1047 Mouse studies suggest PKCE inhibition could help treat both alcohol and nicotine addiction. Full Text | PDF Oxytocin receptor (OXTR) doi:10.1038/scibx.2011.1048 A study in humans suggests modulating OXTR could be useful for treating mood disorders including depression. Full Text | PDF Lysophosphatidic acid receptor 1 (LPAR1; EDG2; LPA1) doi:10.1038/scibx.2011.1049 A study in mice suggests LPAR1 antagonists may help prevent or treat hemorrhage-associated fetal hydrocephalus (FH). Full Text | PDF Solute carrier family 7 member 11 cystine glutamate transporter (SLC7A11; xCT) doi:10.1038/scibx.2011.1050 Mouse studies suggest the xCT blocker Azulfidine sulfasalazine could help reduce seizures associated with glioma. Full Text | PDF Distillery: Techniques Disease models Top Modeling HIV infection with transgenic cats doi:10.1038/scibx.2011.1051 Transgenic cats expressing antiviral host factors could be used as models to develop new treatments for HIV infection. Full Text | PDF Mouse model of hypokalemic periodic paralysis doi:10.1038/scibx.2011.1052 A mouse model of hypokalemic periodic paralysis could aid the development of new treatments for the disease. Full Text | PDF Transgenic, metabotropic glutamate receptor subtype 5 (mGluR5; GRM5)-expressing mouse models of melanoma doi:10.1038/scibx.2011.1053 Transgenic mice that express wild-type mGlur5 in melanocytes could be useful for identifying melanoma therapies. Full Text | PDF Drug platforms Top Genetically attenuated Mycobacterium smegmatis as a tuberculosis (TB) vaccine vector doi:10.1038/scibx.2011.1054 Genetically attenuated strains of M. smegmatis could be used as vectors for TB vaccines. Full Text | PDF Markers Top Using CD34-negative and stem cell factor receptor tyrosine kinase (c-Kit; KIT; CD117)-positive cell levels to predict systemic mastocytosis severity doi:10.1038/scibx.2011.1055 Studies in patient samples suggest CD34−/c-Kit+ cell levels could predict systemic mastocytosis prognosis. Full Text | PDF You have been sent this Table of Contents Alert because you have opted in to receive it. You can change or discontinue your e-mail alerts at any time, by modifying your preferences on your nature.com account at: www.nature.com/myaccount (You will need to log in to be recognised as a nature.com registrant) For further technical assistance, please contact our registration department For print subscription enquiries, please contact our subscription department For other enquiries, please contact our customer feedback department Nature Publishing Group | 75 Varick Street, 9th Floor | New York | NY 10013-1917 | USA Nature Publishing Group's worldwide offices: London - Paris - Munich - New Delhi - Tokyo - Melbourne San Diego - San Francisco - Washington - New York - Boston Macmillan Publishers Limited is a company incorporated in England and Wales under company number 785998 and whose registered office is located at Brunel Road, Houndmills, Basingstoke, Hampshire RG21 6XS. © 2011 Nature Publishing Group, a division of Macmillan Publishers Limited. All Rights Reserved.